Deog-Yeon Jo, M.D. Ph.D.
Korean J Hematol 2011; 46(4): 209-210Seok Jin Kim, M.D. Ph.D.
Korean J Hematol 2011; 46(4): 211-213Michele Bibas, and Andrea Baiocchini
Korean J Hematol 2011; 46(4): 214Dahae Won, Chan Jeoung Park, and Jai Won Chang
Korean J Hematol 2011; 46(4): 215Raja Rajalingam
Korean J Hematol 2011; 46(4): 216-228Svjetlana Raus, Silvia Coin, and Vladia Monsurrò
Korean J Hematol 2011; 46(4): 229-238Khaldoun Alkayed, and Kandice Kottke-Marchant
Korean J Hematol 2011; 46(4): 239-243Ha-Yon Kim, Ji-Young Hwang, Yoon-Suk Oh, Seong-Woo Kim, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, Young-Jun Yang, and Deog-Yeon Jo
Korean J Hematol 2011; 46(4): 244-252Se Youn Choi, Inho Kim, Nam Joong Kim, Seung-Ah Lee, Youn-Ak Choi, Ji-Yeon Bae, Ji Hyun Kwon, Pyoeng Gyun Choe, Wan Beom Park, Sung-Soo Yoon, Seonyang Park, Byoung Kook Kim, and Myoung-Don Oh
Korean J Hematol 2011; 46(4): 253-257Meerim Park, Kyung Nam Koh, Jong Jin Seo, and Ho Joon Im
Korean J Hematol 2011; 46(4): 258-264
Chimeric status of patients with high-level mixed chimerism.
|@|~(^,^)~|@|Receiver operating characteristic curve used to determine the optimal CD34+ cell number cut-off value for predicting chimerism.
|@|~(^,^)~|@|Kaplan-Meier curves showing overall survival in high-level mixed chimerism and transient or low-level mixed chimerism groups.
|@|~(^,^)~|@|Kaplan-Meier curves showing event-free survival in high-level mixed chimerism and transient or low-level mixed chimerism groups.